PHARMA: Unable to Go It Alone, Co. Pursues Strategic Alternatives
Diet pill maker Orexigen Therapeutics, one of San Diego’s struggling public companies, may soon auction itself off to the highest bidder in an attempt to fortify its finances.
The FDA has cleared Carlsbad-based Acutus Medical’s AcQMap system.
Spine surgery and medical device company NuVasive reported solid revenue growth in its third quarter earnings report, driven by strong international sales.
Neighborhood Healthcare, which has 12 health centers in San Diego and Riverside, has tapped Rakesh Patel as its new CEO.
San Diego drugmaker Ignyta Inc. is piggybacking off recent positive press by raising $160 million in a new stock offering.
Regulators with the U.S. Food and Drug Administration have handed Neurocrine Biosciences a special classification for one of its drug programs, granting the company a number of perks.
BIOTECH: Collectively Stocks Up 4% But Gains Not Spread Equally
The stock performance of San Diego’s public life science companies saw a modest gain in the third quarter, with a few high-performing drugmakers pulling up the region’s average.
Medical device and surgery company NuVasive has launched Modulus XLIF, titanium implants that are 3-D-printed, expanding the company’s surgical offerings.
Arcturus Therapeutics Inc., a small local biotech that reversed its way into the public markets a few weeks ago, has struck a comprehensive research deal with pharmaceutical giant Johnson & Johnson.
Medical device maker CareFusion will eliminate about 81 positions in San Diego as part of a strategic shift.
Carlsbad drugmaker Ionis Pharmaceuticals has earned $10 million from its Big Pharma partner Biogen for taking one of its experimental drugs to the clinic.
Following its failure in the clinic, San Diego’s fat-busting biotech Neothetics is folding into a growing local company called Evofem Biosciences.
The venture capital firm founded by San Diego’s DNA instrument giant Illumina Inc. has raised a $230 million fund to fuel genomics startups.
Last year, a top San Diego executive snatched up a once-failed drug from pharma giant Sanofi and formed a new biotech startup around the medicine.k
Local biotech AnaptysBio is capitalizing on its skyrocketing stock performance this week with an announcement that the company plans to raise $99 million in a stock offering this month.